More articles about: Rogel Cancer Center

The American Thyroid Association first published guidelines for managing differentiated thyroid cancer in 1996. The current updates consider every aspect of the patient’s journey, including diagnosis, monitoring and treatment. Megan Haymart answers questions about understanding the risk for thyroid cancer, active surveillance and current treatment options.

An expert discusses the long time usage of radiation therapy for non-cancer diseases in other countries that are now available in the United States.

Pediatric cancer patient at Michigan Medicine was diagnosed with ATRT and underwent chemotherapy and radiation. Four years later, he’s doing well.

Emilia Pigeon was diagnosed with neuroblastoma, a type of cancer that starts in immature nerve cells. She was treated with chemotherapy and surgery and continues to do well.

Rogel Cancer Center researcher Steven J. Katz, M.D., M.P.H., on how genetic testing results impact both the cancer patient and their family.

A student aspiring to be a filmmaker graduates from Michigan while battling cancer through his years at school.

A team of researchers from Michigan Medicine tracked how glucose is used in glioblastoma tumor cells. They showed that dietary interventions can slow brain cancer growth in mice.

Sidney Ritchie’s aggressive brain cancer diagnosis has changed her life, and now, in her new reality, she finds meaning and purpose through connection, volunteering, and “showing up fully”

Immunotherapy uses the body’s immune system to recognize and destroy cancer cells. However, many patients are resistant to this therapy, which poses a challenge to their treatment. A study led by researchers from the University of Michigan showed that targeting CDK12/13 improves the effectiveness of cancer therapies.

Mike Nagle’s osteosarcoma journey, before he even had symptoms, was nothing short of a miracle, he explains in this article.

Patrick Grohar answers questions about symptoms, treatments and research initiatives that are being undertaken with respect to Ewing Sarcoma.

A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment. 

A study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene—commonly altered in prostate cancer—drive tumor initiation formation and therapeutic resistance.

When treating for localized prostate cancer, surgery and radiation are usually what people hear about. However, there are other treatments that could be options under a heading of focal therapy. Dr. Andrew Wood, a urologic oncologist with U-M Health Rogel Cancer Center’s Weiser Center for Prostate Cancer talks about these options and which patients could benefit from them.

As recommendations suggest extending hormone-based breast cancer treatment to 10 years for some patients, a recent study sheds light on whether patients are opting for it.